Last reviewed · How we verify
Cabotegravir, Rilpivirine Drug Combination
Cabotegravir, Rilpivirine Drug Combination is a Antiretroviral combination (INSTI + NNRTI) Small molecule drug developed by University Paris 7 - Denis Diderot. It is currently in Phase 3 development for HIV-1 infection treatment, HIV-1 pre-exposure prophylaxis (PrEP). Also known as: CAB, RPV.
This combination inhibits HIV integrase and reverse transcriptase to prevent viral replication and integration into host DNA.
This combination inhibits HIV integrase and reverse transcriptase to prevent viral replication and integration into host DNA. Used for HIV-1 infection treatment, HIV-1 pre-exposure prophylaxis (PrEP).
At a glance
| Generic name | Cabotegravir, Rilpivirine Drug Combination |
|---|---|
| Also known as | CAB, RPV |
| Sponsor | University Paris 7 - Denis Diderot |
| Drug class | Antiretroviral combination (INSTI + NNRTI) |
| Target | HIV integrase and HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | Phase 3 |
Mechanism of action
Cabotegravir is an integrase strand transfer inhibitor (INSTI) that blocks HIV integrase, preventing the virus from inserting its genetic material into human chromosomes. Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks the enzyme responsible for converting HIV RNA into DNA. Together, they provide dual-mechanism antiretroviral activity for HIV treatment and prevention.
Approved indications
- HIV-1 infection treatment
- HIV-1 pre-exposure prophylaxis (PrEP)
Common side effects
- Injection site reactions
- Headache
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- Combined Injectable Treatment for HIV and OUD (PHASE2)
- More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents (PHASE1, PHASE2)
- Study Using CABENUVA™ for the Treatment of Human Immunodeficiency Virus (HIV)-1, Administered in Infusion Centers (IC) or Alternate Sites of Administration (ASA) in the United States (U.S.) (PHASE4)
- Long-acting Injectable Antiretroviral Treatment to Improve HIV Treatment Among Justice-involved Persons Being Released to the Community
- Improving HIV-1 Control in Africa with Long Acting Antiretrovirals (PHASE3)
- Outcomes of the PLHIV With Suboptimal Viral Suppression to Injectable Long-acting Antiretrovirals (PHASE3)
- A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects (PHASE2)
- A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cabotegravir, Rilpivirine Drug Combination CI brief — competitive landscape report
- Cabotegravir, Rilpivirine Drug Combination updates RSS · CI watch RSS
- University Paris 7 - Denis Diderot portfolio CI
Frequently asked questions about Cabotegravir, Rilpivirine Drug Combination
What is Cabotegravir, Rilpivirine Drug Combination?
How does Cabotegravir, Rilpivirine Drug Combination work?
What is Cabotegravir, Rilpivirine Drug Combination used for?
Who makes Cabotegravir, Rilpivirine Drug Combination?
Is Cabotegravir, Rilpivirine Drug Combination also known as anything else?
What drug class is Cabotegravir, Rilpivirine Drug Combination in?
What development phase is Cabotegravir, Rilpivirine Drug Combination in?
What are the side effects of Cabotegravir, Rilpivirine Drug Combination?
What does Cabotegravir, Rilpivirine Drug Combination target?
Related
- Drug class: All Antiretroviral combination (INSTI + NNRTI) drugs
- Target: All drugs targeting HIV integrase and HIV reverse transcriptase
- Manufacturer: University Paris 7 - Denis Diderot — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Virology
- Indication: Drugs for HIV-1 infection treatment
- Indication: Drugs for HIV-1 pre-exposure prophylaxis (PrEP)
- Also known as: CAB, RPV